Search - tctmd.com

Displaying 1 - 20 of 21

Sort: Relevancy | Date

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

News Conference News ACC 2025

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

Michael O'Riordan

April 02, 2025

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

News Conference News TCT 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

September 26, 2019

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

News Conference News TCT 2019

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Yael L. Maxwell

September 26, 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

August 22, 2019

Rivaroxaban in Addition to DAPT Lowers Death, MI, Stroke in ACS, Heart Failure Patients: Meta-analysis

News Conference News CRT 2019

Rivaroxaban in Addition to DAPT Lowers Death, MI, Stroke in ACS, Heart Failure Patients: Meta-analysis

Yael L. Maxwell

March 03, 2019

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

News Conference News TCT 2018

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

Michael O'Riordan

September 24, 2018

ACC 2018, Day Three: Gout, Hypertension, and Diabetes Dominate Opening Late Breaker

News Conference News ACC 2018

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

March 12, 2018

GEMINI-ACS-1 Substudy: P2Y12 Inhibitor Switching Is Uncommon After ACS

News Conference News AHA 2017

GEMINI-ACS-1 Substudy: P2Y12 Inhibitor Switching Is Uncommon After ACS

Yael L. Maxwell

November 14, 2017

Angiography, Revascularization Safe in Acute MI Patients Taking OACs for Atrial Fibrillation

News Conference News AHA 2017

Angiography, Revascularization Safe in Acute MI Patients Taking OACs for Atrial Fibrillation

Michael O'Riordan

November 13, 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

News Conference News ESC 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

August 27, 2017

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

News Conference News ACC 2017

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

March 18, 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

March 10, 2017

News Conference News AHA 2016

Rivaroxaban-Based Double or Triple Therapy Cuts Bleeding in Patients With A-fib Undergoing PCI: PIONEER AF-PCI

November 14, 2016

News Conference News ACC 2016

Comparing the Novel Oral Anticoagulants: Effectiveness Similar, but Apixaban May Come With Less Bleeding

April 06, 2016

News Conference News AHA 2015

Reversal Agents Safely Stop Effects of Novel Oral Anticoagulants

Yael L. Maxwell

November 10, 2015

News Conference News ESC 2012

ESC Congress 2012: Diverse Lineup of Practice-Changing Presentations

September 04, 2012

News Conference News ESC 2012

Low-Dose Rivaroxaban Curbs Thrombotic Events in STEMI Patients

August 27, 2012

News Conference News ACC 2012

ACC-i2 Scientific Session 2012: Cooperation Key as Practice Changing Results Released

Yael L. Maxwell

April 02, 2012

News Conference News

ESC Congress 2011: Drugs, Devices Work Together

September 06, 2011

News Conference News

RUBY-1: Yet Another Novel Anticoagulant Tested in ACS Patients on Antiplatelets

August 31, 2011

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.